Skip to main content
logo
UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
46.96
+1.36 (2.98%)
At close: Aug 7, 2026, 4:00 PM EDT
47.12
+0.16 (0.34%)
After-hours: Aug 7, 2026, 7:55 PM EDT

UroGen Pharma Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
188.73109.7990.482.7164.3648.04
Revenue Growth
100.27%21.45%9.29%28.52%33.96%307.17%
Gross Profit
171.4697.3481.5273.3556.742.89
Operating Income
-66.65-124.86-96.78-65.54-79.04-92.29
Net Income
-97.64-153.49-126.87-102.24-109.78-110.82
Earnings Per Share
-1.98-3.19-2.96-3.55-4.81-4.96
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
107.98120.46236.69136.9799.9689.14
Total Debt
196.13128.33123.3999.499.120.4
Net Cash (Debt)
-88.15-7.88113.337.570.8488.74
Net Cash Growth
--201.54%4367.66%-99.05%-11.72%
Net Cash Per Share
-1.78-0.162.641.300.043.97

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-158.92-162.44-96.77-76.38-87.56-84.89
Capital Expenditures
-0.22-0.29-0.3-0.19-0.25-0.75
Free Cash Flow
-159.14-162.73-97.06-76.57-87.81-85.64
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
90.85%88.66%90.18%88.68%88.11%89.27%
Operating Margin
-35.32%-113.73%-107.06%-79.23%-122.82%-192.11%
Pretax Margin
-51.98%-139.74%-137.22%-118.87%-167.86%-227.66%
Profit Margin
-51.73%-139.81%-140.35%-123.61%-170.58%-230.67%
FCF Margin
-84.32%-148.22%-107.37%-92.57%-136.45%-178.27%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
12.1610.314.985.893.194.45